Pfizer stock price is steady at $28.50 following a muted session. The sideways price action corresponds with low volatility conditions across the healthcare sector, indicative of investor patience for catalysts. All of this means this deal with the U.S. is fantastic news for Pfizer as it erases key risks without hurting earnings potential. At the same time, Pfizer's stock remains cheap, trading at only 8x forward earnings estimates even after the recent gain. And that's why now is a great time to get in on this stock -- and potentially win as Pfizer enters a new era of growth in the coming years. Pfizer Inc. (NYSE:PFE) is a global biopharmaceutical company that manufactures, develops, markets, and sells biopharmaceutical products worldwide. It advances wellness, prevention, treatment, and cures in developing and emerging markets. Pfizer stock price is trading at $28.46, with RSI levels approaching oversold territory. Technical analysts suggest a possible bounce if buyers return ahead of the next quarterly earnings release.
